Acceleron Pharma's ACE-041 Combined With a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma  
4/3/2012 10:28:14 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced that collaborators at Beth Israel Deaconess Medical Center presented preclinical data today at the American Association for Cancer Research (AACR) Annual Meeting 2012 which showed that ACE-041, an activin-receptor like kinase 1 (ALK1) receptor ligand trap, when used in combination with sunitinib, inhibited tumor growth in a model of VEGF-inhibitor-resistant renal cell carcinoma (RCC).